Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Fina Biosolutions
Deal Size : Undisclosed
Deal Type : Licensing Agreement
VALANX Biotech And Fina Biosolutions Launch ClickCRM for Vaccine R&D
Details : The licensing agreement will commercialize ready-to-conjugate vaccine carrier protein CRM197 enabling rapid development of conjugate vaccines such as the pneumococcal and meningococcal vaccines.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
October 29, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Fina Biosolutions
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Azelastine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The potent anti-SARS-CoV-2 activity of azelastine formulated in a nasal spray was demonstrated in an experimental reconstituted human nasal tissue model and was evident at a lower dose than present in commercially available products.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 17, 2020
Lead Product(s) : Azelastine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Carrageenan
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data from Marinomed’s cell-culture study confirm that Carragelose® works in a dose-dependent manner to strongly reduce the infection of cells from the SARS-CoV-2 virus.
Product Name : Carragelose
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 16, 2020
Lead Product(s) : Carrageenan
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SARS-CoV-2 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Acquisition
Merck Completes Acquisition of Themis
Details : An initial focus of this agreement is acceleration of the development of a measles vector-based SARS-CoV-2 vaccine candidate. This candidate is currently in pre-clinical development, and clinical studies are planned to start later in 2020.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
June 19, 2020
Lead Product(s) : SARS-CoV-2 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : PP-OO1
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
The Viennese Biotech Company Panoptes Pharma Gmbh Has A Promising Active Ingredient Against COVID-19
Details : Panoptes Pharma GmbH has been able to demonstrate that COVID-19 treatment with PP-001 inhibits excessive release of certain cytokines.
Product Name : PP-OO1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 25, 2020
Lead Product(s) : PP-OO1
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable